Royalty Pharma (RPRX) Earnings Date, Estimates & Call Transcripts $32.83 -0.26 (-0.79%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$32.87 +0.04 (+0.12%) As of 05/21/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Royalty Pharma Earnings Summary Royalty Pharma announced Q1 2025 earnings on May 8, 2025, reporting an EPS of $1.06, which topped the consensus estimate of $0.99 by $0.07. Quarterly revenue was reported to be $839 million, above the consensus estimate of $724.69 million. With a trailing EPS of $1.85 and a P/E Ratio of 22.64, Royalty Pharma's earnings are expected to grow 8.24% next year, from $4.49 to $4.86 per share. Latest Q1 Earnings DateMay. 8EstimatedConsensus EPS (May. 8) $0.99 Actual EPS (May. 8) $1.06 Beat By $0.07 Actual Revenue (May. 8) $839.00MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)SEC FilingSlide DeckFull Screen Slide DeckPowered by Get Royalty Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRPRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RPRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Royalty Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $4.49 EPSNext Year EPS Consensus Estimate $4.86 EPS Royalty Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025$0.99$1.06+$0.07$0.41$724.69M$839.00M2/11/2025Q4 2024$0.99$1.15+$0.16$0.35$743.60M-8/8/2024Q2 2024$0.95$0.96+$0.01$1.75$600.83M$537.00M5/9/2024Q1 2024$0.96$0.98+$0.02$1.95$671.45M$568.00M2/15/2024Q4 2023$1.03$1.15+$0.12$1.47$702.90M$736.00M11/8/2023Q3 2023$0.81$0.79 -$0.02$1.46$640.96M$637.00M8/8/2023Q2 2023$0.83$0.85+$0.02$1.32$538.52M$545.00M Royalty Pharma Earnings - Frequently Asked Questions When did Royalty Pharma announce their last quarterly earnings? Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earning data on Thursday, May 8, 2025. Learn more on RPRX's earnings history. Did Royalty Pharma beat their earnings estimates last quarter? In the previous quarter, Royalty Pharma (NASDAQ:RPRX) reported $1.06 earnings per share (EPS) to beat the analysts' consensus estimate of $0.99 by $0.07. Learn more on analysts' earnings estimate vs. RPRX's actual earnings. How can I listen to Royalty Pharma's earnings conference call? The conference call for Royalty Pharma's latest earnings report can be listened to online. Listen to Conference Call How can I read Royalty Pharma's conference call transcript? The conference call transcript for Royalty Pharma's latest earnings report can be read online. Read Transcript How can I view Royalty Pharma's earnings report? Royalty Pharma's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Royalty Pharma generate each year? Royalty Pharma (NASDAQ:RPRX) has a recorded annual revenue of $2.26 billion. How much profit does Royalty Pharma generate each year? Royalty Pharma (NASDAQ:RPRX) has a recorded net income of $858.98 million. RPRX has generated $1.85 earnings per share over the last four quarters. What is Royalty Pharma's price-to-earnings ratio? Royalty Pharma (NASDAQ:RPRX) has a trailing price-to-earnings ratio of 22.64 and a forward price-to-earnings ratio of 7.31. The price/earnings-to-growth ratio is 2.31. What is Royalty Pharma's EPS forecast for next year? Royalty Pharma's earnings are expected to grow from $4.49 per share to $4.86 per share in the next year, which is a 8.24% increase. More Earnings Resources from MarketBeat Related Companies ZTS Earnings Date CORT Earnings Date JAZZ Earnings Date PRGO Earnings Date SUPN Earnings Date PCRX Earnings Date OMER Earnings Date NKTR Earnings Date ASMB Earnings Date CPIX Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:RPRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
